Abstract
The combined use of a fibrinolytic and a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor to target the fibrin and platelet components of occlusive thrombi offers the potential for more rapid and complete reperfusion in patients with acute myocardial infarction (MI), although there have been concerns about the safety of this combination therapy. Data from the recent GUSTO‐V and the ASSENT‐3 trials support the use of this regimenin that the 30‐day death or non‐fatal reinfarction rate (7 days) in GUSTO‐V and death or in‐hospital reinfarction or in‐hospital refractory ischemia rate in ASSENT‐3 were reduced (p = 0.001 and p = 0.0001, respectively). The need for revascularization in both these trials was also reduced significantly. There was no increased risk of intracranial hemorrhage or stroke with the combination therapy, but an increased rate of nonintracranial severe or major bleeding was observed. At present, patients aged > 75 years should not receive combination therapy. Further studies in subgroup patient populations are warranted.
Keywords: glycoprotein IIb/IIIa receptor inhibitors, thrombolysis, heparin
Full Text
The Full Text of this article is available as a PDF (61.5 KB).
References
- 1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) : Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402 [PubMed] [Google Scholar]
- 2. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360 [PubMed] [Google Scholar]
- 3. Simoons ML, Serruys PW, van den Brand M, Res J, Verheugt FWA, Krauss XH, Remme WJ, Bär F, de Zwaan C, van der Laarse A, Vermeer F, Lubsen J: Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717–728 [DOI] [PubMed] [Google Scholar]
- 4. The GUSTO Angiographic Investigators : The effects of tissue plasminogen activator, streptokinase, or both on coronary‐artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 5. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF: Extended mortality benefit of early postinfarction reperfusion. GUSTO‐I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97: 1549–1556 [DOI] [PubMed] [Google Scholar]
- 6. The EPIC Investigators : Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. N Engl J Med 1994; 330: 956–961 [DOI] [PubMed] [Google Scholar]
- 7. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–2835 [DOI] [PubMed] [Google Scholar]
- 8. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation 1998; 97: 211–218 [DOI] [PubMed] [Google Scholar]
- 9. Cannon CP: Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1395–1402 [DOI] [PubMed] [Google Scholar]
- 10. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381–389 [DOI] [PubMed] [Google Scholar]
- 11. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ: Combined accelerated tissue‐plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo‐controlled, dose‐ranging trial. IMPACT‐AMI Investigators. Circulation 1997; 95: 846–854 [DOI] [PubMed] [Google Scholar]
- 12. The PARADIGM Investigators : Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998; 32: 2003–2010 [DOI] [PubMed] [Google Scholar]
- 13. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E: Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720–2732 [DOI] [PubMed] [Google Scholar]
- 14. Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E: Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14. Eur Heart J 2000; 21: 1944–1953 [DOI] [PubMed] [Google Scholar]
- 15. Ronner E, van Kesteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, Veltri E, Lorenz T, Neuhaus K, Simoons ML: Combined therapy with streptokinase and integrilin (abstr). J Am Coll Cardiol 1998; 31 (suppl A): 191A [Google Scholar]
- 16. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group : Trial of abciximab with and without low‐dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788–2794 [DOI] [PubMed] [Google Scholar]
- 17. Brener SJ, Zeymer U, Adgey AAJ, Vrobel TR, Ellis SG, Neuhaus KL, Juran N, Ivanc TB, Ohman EM, Strony J, Kitt M, Topol EJ, for the INTRO AMI investigators : Eptifibatide and low‐dose tissue plasminogen activator in acute myocardial infarction: The integrilin and low‐dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39: 377–386 [DOI] [PubMed] [Google Scholar]
- 18. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)‐3 Investigators : Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The AS SENT‐3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–613 [DOI] [PubMed] [Google Scholar]
- 19. Topol EJ, The GUSTO V Investigators : Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001; 357: 1905–1914 [DOI] [PubMed] [Google Scholar]
- 20. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand J‐P, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf F, for the ENTIRE‐TIMI 23 Investigators : Enoxaparin as adjunctive antithrombin therapy for ST‐elevation myocardial infarction: Results of the ENTIRE‐Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002; 105: 1642–1649 [DOI] [PubMed] [Google Scholar]
- 21. Giugliano RP, Roe MT, Zeymer U, Gibson M, Fox NL, Greenberg S, Kitt MM, Strony JT, Braunwald E, Harrington RA: Restoration of epicardial and myocardial perfusion in acute ST‐elevation myocardial infarction with combination eptifibatide + reduced‐dose tenecteplase: Dose‐finding results from the INTEGRITI trial (abstr). Circulation 2001; 104 (suppl II):II–538 [Google Scholar]
- 22. Verheugt FWA: GUSTO V: The bottom line of fibrinolytic reperfusion therapy. Lancet 2001; 357: 1898–1899 [DOI] [PubMed] [Google Scholar]
- 23. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van Der Wieken R, Van De Werf F, Braunwald E: Abciximab improves both epicardial flow and myocardial reperfusion in ST‐elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation 2000; 101: 239–243 [DOI] [PubMed] [Google Scholar]